GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poniard Pharmaceuticals Inc (OTCPK:PARD) » Definitions » ROC (Joel Greenblatt) %

Poniard Pharmaceuticals (Poniard Pharmaceuticals) ROC (Joel Greenblatt) % : -69,730.23% (As of Sep. 2011)


View and export this data going back to 2012. Start your Free Trial

What is Poniard Pharmaceuticals ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Poniard Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2011 was -69,730.23%.

The historical rank and industry rank for Poniard Pharmaceuticals's ROC (Joel Greenblatt) % or its related term are showing as below:

PARD's ROC (Joel Greenblatt) % is not ranked *
in the Biotechnology industry.
Industry Median: -334.375
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

Poniard Pharmaceuticals's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Poniard Pharmaceuticals ROC (Joel Greenblatt) % Historical Data

The historical data trend for Poniard Pharmaceuticals's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poniard Pharmaceuticals ROC (Joel Greenblatt) % Chart

Poniard Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5,321.80 -4,295.63 -4,381.19 -6,026.38 -19,650.75

Poniard Pharmaceuticals Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -27,840.94 -30,918.03 -30,065.12 -49,522.58 -69,730.23

Competitive Comparison of Poniard Pharmaceuticals's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Poniard Pharmaceuticals's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Poniard Pharmaceuticals's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poniard Pharmaceuticals's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Poniard Pharmaceuticals's ROC (Joel Greenblatt) % falls into.



Poniard Pharmaceuticals ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2011 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.502) - (2.087 + 0 + 0)
=-1.585

Working Capital(Q: Sep. 2011 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.268) - (2.979 + 0 + 0)
=-2.711

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Poniard Pharmaceuticals for the quarter that ended in Sep. 2011 can be restated as:

ROC (Joel Greenblatt) %(Q: Sep. 2011 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2011  Q: Sep. 2011
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-14.992/( ( (0.025 + max(-1.585, 0)) + (0.018 + max(-2.711, 0)) )/ 2 )
=-14.992/( ( 0.025 + 0.018 )/ 2 )
=-14.992/0.0215
=-69,730.23 %

Note: The EBIT data used here is four times the quarterly (Sep. 2011) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Poniard Pharmaceuticals  (OTCPK:PARD) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Poniard Pharmaceuticals ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Poniard Pharmaceuticals's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Poniard Pharmaceuticals (Poniard Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.
Executives
Michael S Perry officer: President & CMO C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
Ron Martell director, officer: Chief Executive Officer PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gary A Lyons director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
David R Stevens director 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114
Gerald Phd Mcmahon director 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114
Carl Goldfischer director 161 WEST 61ST STREET, NEW YORK NY 10022
Fred B Craves director 750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
Simon Nicholas J Iii director, 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Gregory L Weaver officer: Chief Financial Officer 185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107
Kurt Wheeler 10 percent owner 801 GATEWAY BLVD, STE 410, SAN FRANCISCO CA 94080
Mpm Asset Management Investors 2005 Bviii Llc 10 percent owner C/O MPM ASSET MANAGEMENT, 111 HUNTINGTON AVENUE 31ST FLOOR, BOSTON MA 02199
Nicholas Galakatos 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Dennis Henner 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Michael Steinmetz 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Luke Evnin 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116

Poniard Pharmaceuticals (Poniard Pharmaceuticals) Headlines